This guide sets out who qualifies for Mounjaro on the NHS, the BMI and condition criteria, how the rollout is phased, and how England, Scotland and Wales differ. It draws on NICE, the NHS and the devolved-nation sources. Northern Ireland arrangements are still developing and are not covered here.
Is Mounjaro available on the NHS?
Yes, but with important qualifications. Tirzepatide is available either on the NHS where you meet the criteria for your nation, or privately on prescription from a registered pharmacy 4. The NHS criteria are much narrower than the medicine's licence, and the rollout is being introduced in stages because the eligible population is large 1.
The single biggest source of confusion is the gap between the licence and NHS funding. The licence allows weight-management use from a BMI of 30 (or 27 with a weight-related condition) 5, but NHS funding in England is limited to higher thresholds and phased over several years 1. So you can be eligible by the licence and still not yet eligible on the NHS.
The sections below take each nation in turn. Our complete Mounjaro guide gives the wider clinical picture, and this page focuses specifically on the NHS route.
NHS eligibility in England
In England, NICE recommends tirzepatide for managing overweight and obesity in adults only if they have a BMI of at least 35 kg/m2 and at least one weight-related condition, with the medicine provided under a commercial arrangement 1. For people from several ethnic backgrounds at equivalent risk at a lower BMI, the threshold is reduced by 2.5 kg/m2 1.
Access is being phased in over several years through the NHS England commissioning plan. Under that plan, eligibility depends on your BMI and how many of five weight-related conditions you have (high blood pressure, abnormal blood fats, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes) 1. You may be eligible now with four or more of those conditions and a BMI of 40 or above; from around June 2026 with four or more conditions and a BMI of 35 to 39.9; and from around March 2027 with three conditions and a BMI of 40 or above 1.
There is also a review built in: if less than 5 percent of starting weight is lost after six months on the highest tolerated dose, the prescriber decides whether to continue 1. Tirzepatide can be prescribed in primary care or specialist weight management services in England 1.
The phasing is the part that most affects whether you can get it today. The earliest groups are those with the highest BMI and the most weight-related conditions, with eligibility widening in stages over roughly three years from when the guidance was published 1. NICE judged that tirzepatide alongside diet and exercise support is more effective than that support alone, which is why it is recommended within these cost-effectiveness-based thresholds rather than at the full breadth of the licence 1.
NHS access in Scotland
In Scotland, the Scottish Medicines Consortium accepts tirzepatide for restricted use within NHS Scotland, for adults with a BMI of 30 kg/m2 or above and at least one weight-related condition, provided it is supplied under the agreed patient access scheme 2. A lower BMI cut-off may be appropriate for people from minority ethnic groups at equivalent risk 2.
That BMI threshold is lower than NICE's BMI 35 starting point in England, which is one of the clearest examples of how access differs by nation 12. The SMC advice published in June 2024 is what governs the Scottish position 2.
As in England, the medicine is used alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment 26. How services deliver it locally is a matter for NHS Scotland.
The lower BMI threshold in Scotland is a good illustration of why it matters to check the rules for your own nation rather than relying on general UK coverage. Someone with a BMI of 32 and a weight-related condition might fall outside the England NICE starting threshold of 35 but within the Scottish SMC position of 30 or above with a comorbidity 12. The medicine is the same; what differs is which NHS will fund it for whom, which is exactly the kind of detail a GP or pharmacist can confirm against your circumstances 2.
Considering treatment for weight management? You can start an assessment with a Cloud Pharmacy clinician, who will review your medical history and confirm whether treatment is appropriate.
NHS access in Wales
In Wales, a Welsh Government circular sets out that, for weight loss, tirzepatide should currently be started only through NHS specialist weight management services, with no new initiations elsewhere, while a national approach is worked out 3. NICE extended the implementation period substantially given the large eligible population, so full rollout is happening gradually 3.
The circular is explicit that NHS England's commissioning guidance does not apply in Wales, and that Welsh Ministers will set out extended deployment arrangements once the work is complete 3. In the meantime, the specialist-service route is the NHS option in Wales 3.
The practical effect is that NHS access in Wales is, for now, more restricted than the licence and routed through specialist services, so many people there look at the private route while the national approach develops 34.
What you pay, and the private alternative
If tirzepatide is prescribed on the NHS, what you pay depends on how it is supplied and where you live. In England, the standard NHS prescription charge is £9.90 per item, with exemptions for some people, while NHS prescriptions are free in Scotland and Wales 7. Where it is supplied through a specialist service rather than dispensed against a prescription, it may be provided without a charge 7.
Because NHS funding is narrow and phased, many people who want treatment but do not yet qualify look at the private route, which is self-funded and supplied on prescription from a registered pharmacy 4. The NHS advises buying only from a registered pharmacy, because some websites sell fake weight-loss medicines 4.
Whichever route, the medicine and its criteria are the same idea: it is a prescription-only treatment used alongside diet and activity, and suitability is assessed individually 5. If cost or eligibility is the barrier, it is worth checking whether you might qualify in an upcoming NHS phase 1.
It is worth being clear that the NHS prescription charge and the private price are very different things. The £9.90 charge applies to an NHS prescription in England regardless of what the medicine actually costs the NHS, because the NHS buys tirzepatide under a confidential commercial arrangement 17. The private price, by contrast, is set by the pharmacy and is what people who do not qualify on the NHS pay 4. So the headline gap between the two is really a gap between a subsidised NHS route, open only to those who meet the criteria, and a self-funded private one 14.
How to find out if you qualify
The most reliable way to find out is to speak to your GP or pharmacist about the criteria for your nation, since they can check your BMI and weight-related conditions against the current thresholds 12. The phased nature of the rollout means the answer can change over time, so it is worth asking whether you are likely to become eligible in an upcoming phase even if you do not qualify today 1.
You may also see the term BNF in searches; the British National Formulary is a prescribing reference for clinicians, and the dosing and clinical detail for tirzepatide are set out in its UK Summary of Product Characteristics rather than something patients need to navigate themselves 5. If you are considering the private route, a clinician can confirm whether treatment is appropriate for you 4.
Frequently asked questions
What BMI do you need for Mounjaro on the NHS?
It depends on the nation. In England, NICE recommends it at a BMI of at least 35 with a weight-related condition, phased by how many conditions you have, with a 2.5 kg/m2 lower threshold for several ethnic groups 1. In Scotland, the SMC accepts it at a BMI of 30 or above with a comorbidity 2. The licence itself starts at BMI 30 (or 27 with a condition), which is broader than NHS funding 5.Is Mounjaro free on the NHS?
In England you pay the standard prescription charge of £9.90 per item, with exemptions for some people, while NHS prescriptions are free in Scotland and Wales 7. Where it is supplied through a specialist weight management service it may be provided without a charge 7. The main barrier is eligibility, which is narrow and phased, not the per-item cost 1.Why can I get Mounjaro privately but not on the NHS?
Because NHS funding criteria are much narrower than the medicine's licence and are being phased in 1. The licence allows weight-management use from a BMI of 30 (or 27 with a condition), but NHS funding in England starts at BMI 35 with conditions and rolls out in stages 51. The private route is self-funded and open to people who meet the clinical criteria but not the current NHS phase 4.Is Mounjaro available on the NHS in Scotland and Wales?
In Scotland the SMC accepts it for restricted use at a BMI of 30 or above with a weight-related condition, under a patient access scheme 2. In Wales it is currently started only through NHS specialist weight management services while a national approach is developed 3. Both differ from the England position, and Northern Ireland arrangements are separate 1.How do I find out if I am eligible?
Speak to your GP or pharmacist, who can check your BMI and weight-related conditions against the current criteria for your nation 12. Because access is phased, ask whether you might qualify in an upcoming phase even if you do not today 1. If you are considering the private route, a clinician can confirm whether treatment is appropriate 4.Does Northern Ireland have NHS access to Mounjaro?
Northern Ireland arrangements are developing separately and are not covered in detail here; this guide sets out the England, Scotland and Wales positions, which already differ from each other 123. If you are in Northern Ireland, your GP or pharmacist is the right source for the current local position. The private route, from a registered pharmacy, is also an option across the UK 4.Your next step
Mounjaro is available on the NHS for weight management, but eligibility is narrower than the licence and genuinely differs by nation: England at a BMI of 35 with conditions and phased, Scotland at a BMI of 30 with a comorbidity, and Wales currently through specialist services. The per-item cost is modest where you qualify; the real gate is the criteria.
Speak to your GP or pharmacist to check your eligibility for your nation and whether an upcoming phase might open access, or start a consultation about the private route if you do not yet qualify. Always use a registered pharmacy. And remember that not qualifying today does not mean not qualifying later, since the rollout widens in stages, so it is worth asking where you sit relative to the upcoming phases and checking again as the criteria broaden over the next couple of years.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
